The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020? Clin Genitourin Cancer 2020 Aug;18(4):e478-e483
Date
02/23/2020Pubmed ID
32085986DOI
10.1016/j.clgc.2020.01.003Scopus ID
2-s2.0-85079745146 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Systemic therapy is the mainstay of treatment for metastatic urothelial carcinoma (UC). Responses to first-line platinum-based therapy tend to be short-lived with potential toxicity. Despite the approval of checkpoint inhibitors, the long-term prognosis for patients with metastatic UC remains dismal. Herein we report the case of a patient with a solitary pulmonary metastatic lesion of urothelial origin as the only site of metastatic disease who remained free of disease for more than 2 years without systemic therapy after metastasectomy. We review the literature discussing the role of combined surgical and medical management of oligometastatic UC. As our case illustrates, a growing body of evidence suggests a potential role for a multimodal approach in patients with oligometastatic UC.
Author List
Lemke E, Sahasrabudhe D, Guancial E, Bylow K, Johnson S, Messing E, Kilari DAuthors
Scott C. Johnson MD Associate Professor in the Urologic Surgery department at Medical College of WisconsinDeepak Kilari MD Associate Professor in the Medicine department at Medical College of Wisconsin
Emily A. Lemke DNP Adjunct Assistant Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
HumansMetastasectomy
Prognosis
Urologic Neoplasms
